sanofi
translate
bio
mrna
vaccine
candidate
induced
high
antibody
levels
preclinical
studies
sanofi
translate
bio
mrna
vaccine
candidate
induced
high
antibody
levels
preclinical
studies
vaccine
candidate
induced
potent
neutralizing
antibodies
preclinical
studies
two
doses
induced
neutralizing
antibody
levels
significantly
higher
observed
patients
phase
clinical
trial
anticipated
begin
fourth
quarter
paris
lexington
mass
october
sanofi
pasteur
vaccines
global
business
unit
sanofi
translate
bio
nasdaq
tbio
messenger
rna
mrna
therapeutics
company
today
announced
preclinical
results
vaccine
candidate
virus
causes
disease
preclinical
evaluation
importantly
demonstrated
favorable
immune
response
profile
data
support
selection
clinical
development
phase
clinical
trial
anticipated
begin
fourth
quarter
full
results
available
developed
collaboration
agreement
sanofi
pasteur
translate
bio
tackle
global
pandemic
must
look
strong
knowledge
years
infectious
disease
expertise
promise
new
innovative
technologies
said
thomas
triomphe
executive
vice
president
global
head
sanofi
pasteur
today
presentation
positive
results
another
development
milestone
providing
safe
effective
potential
vaccine
shows
promising
technology
looking
forward
working
next
steps
partner
translate
bio
bring
technology
people
rapid
development
effective
vaccines
address
pandemic
continues
urgent
global
public
health
need
encouraged
progress
made
date
partner
sanofi
pasteur
toward
development
promising
mrna
vaccine
candidate
said
ronald
renaud
chief
executive
officer
translate
bio
preclinical
results
report
paper
demonstrate
ability
elicit
favorable
immune
response
mice
primates
importantly
results
provide
additional
support
using
mrna
platform
potentially
expedite
development
alternative
approaches
traditional
key
preclinical
findings
main
findings
preclinical
studies
demonstrate
potential
elicit
neutralizing
antibodies
mice
four
dose
levels
assessed
µg
per
dose
using
vaccination
schedule
administered
three
weeks
apart
induced
levels
binding
antibodies
neutralizing
antibodies
specific
spike
protein
seroconversion
observed
dose
levels
one
administration
increase
titers
observed
following
second
administration
neutralizing
antibody
titers
observed
across
dose
levels
receiving
regimen
higher
dose
groups
µg
µg
titers
detected
one
administration
pronounced
second
administration
primates
nhps
three
dose
levels
assessed
µg
per
dose
using
vaccination
schedule
three
weeks
apart
potency
assessed
two
types
neutralization
assays
pseudovirus
neutralization
first
administration
majority
nhps
developed
neutralizing
antibodies
reactive
spike
protein
antibody
titers
enhanced
second
administration
nhps
reaching
levels
significantly
higher
human
convalescent
sera
day
also
demonstrated
mice
primates
exhibited
cell
response
preprint
publication
immunogenicity
novel
mrna
vaccine
mice
primates
available
shots
goal
fight
addition
mrna
vaccine
candidate
collaboration
translate
bio
sanofi
collaborating
gsk
vaccine
candidate
using
recombinant
manufacturing
technology
one
sanofi
seasonal
influenza
vaccines
combined
gsk
established
pandemic
adjuvant
platform
companies
announced
start
phase
clinical
trial
adjuvanted
recombinant
vaccine
candidate
september
anticipate
first
results
early
december
support
initiation
pivotal
phase
study
end
year
mrna
vaccines
vaccines
work
mimicking
disease
agents
stimulate
immune
system
building
defense
mechanism
remains
active
body
fight
future
infections
mrna
vaccines
offer
innovative
approach
delivering
nucleotide
sequence
encoding
antigen
antigens
selected
high
potential
induce
protective
immune
response
mrna
vaccines
also
represent
potentially
innovative
alternative
conventional
vaccine
approaches
several
reasons
high
potency
ability
initiate
protein
production
without
need
nuclear
entry
capacity
rapid
development
potential
manufacture
safe
administration
using
delivery
approach
potentially
enables
development
vaccines
disease
areas
vaccination
viable
option
today
additionally
desired
antigen
multiple
antigens
expressed
mrna
without
need
adjust
production
process
offering
maximum
flexibility
efficiency
development
sanofi
pasteur
translate
bio
collaboration
translate
bio
entered
collaboration
exclusive
license
agreement
sanofi
pasteur
vaccines
global
business
unit
sanofi
develop
mrna
vaccines
five
infectious
disease
pathogens
agreement
first
expanded
march
include
development
novel
mrna
vaccine
june
two
companies
built
upon
existing
collaboration
pursue
novel
mrna
vaccines
broadly
address
current
future
infectious
diseases
collaboration
brings
together
sanofi
pasteur
leadership
vaccines
translate
bio
mrna
research
development
expertise
agreement
companies
jointly
conducting
research
development
activities
advance
mrna
vaccines
mrna
vaccine
platform
development
research
term
least
four
years
original
signing
translate
bio
translate
bio
mrna
therapeutics
company
developing
new
class
potentially
transformative
medicines
treat
diseases
caused
protein
gene
dysfunction
prevent
infectious
diseases
generating
protective
immunity
translate
bio
primarily
focused
applying
technology
treat
pulmonary
diseases
caused
insufficient
protein
production
reduction
proteins
modify
disease
translate
bio
lead
pulmonary
candidate
evaluated
inhaled
treatment
cystic
fibrosis
cf
phase
clinical
trial
additional
pulmonary
diseases
evaluated
research
programs
utilize
proprietary
lung
delivery
platform
translate
bio
believes
mrna
delivered
target
tissues
via
multiple
routes
administration
consequently
technology
may
apply
broadly
wide
range
diseases
including
diseases
affect
liver
translate
bio
also
pursuing
development
mrna
vaccines
infectious
diseases
collaboration
sanofi
pasteur
sanofi
sanofi
dedicated
supporting
people
health
challenges
global
biopharmaceutical
company
focused
human
health
prevent
illness
vaccines
provide
innovative
treatments
fight
pain
ease
suffering
stand
suffer
rare
diseases
millions
chronic
conditions
people
countries
sanofi
transforming
scientific
innovation
healthcare
solutions
around
globe
sanofi
empowering
life
sanofi
media
relations
nicolas
kressmann
tel
translate
bio
media
relations
maura
gavaghan
tel
mgavaghan
sanofi
investor
relations
paris
eva
arnaud
delepine
yvonne
naughton
sanofi
investor
relations
north
america
felix
lauscher
fara
berkowitz
suzanne
greco
ir
main
line
tel
ir
translate
bio
investor
relations
teri
dahlman
tel
tdahlman
sanofi
statements
press
release
contains
statements
defined
private
securities
litigation
reform
act
amended
statements
statements
historical
facts
statements
include
projections
estimates
underlying
assumptions
statements
regarding
plans
objectives
intentions
expectations
respect
future
financial
results
events
operations
services
product
development
potential
statements
regarding
future
performance
statements
generally
identified
words
expects
anticipates
believes
intends
estimates
plans
similar
expressions
although
sanofi
management
believes
expectations
reflected
statements
reasonable
investors
cautioned
information
statements
subject
various
risks
uncertainties
many
difficult
predict
generally
beyond
control
sanofi
could
cause
actual
results
developments
differ
materially
expressed
implied
projected
information
statements
risks
uncertainties
include
among
things
uncertainties
inherent
research
development
future
clinical
data
analysis
including
post
marketing
decisions
regulatory
authorities
fda
ema
regarding
whether
approve
drug
device
biological
application
may
filed
product
candidates
well
decisions
regarding
labelling
matters
could
affect
availability
commercial
potential
product
candidates
fact
product
candidates
approved
may
commercially
successful
future
approval
commercial
success
therapeutic
alternatives
sanofi
ability
benefit
external
growth
opportunities
complete
related
transactions
obtain
regulatory
clearances
risks
associated
intellectual
property
related
pending
future
litigation
ultimate
outcome
litigation
trends
exchange
rates
prevailing
interest
rates
volatile
economic
market
conditions
cost
containment
initiatives
subsequent
changes
thereto
impact
us
customers
suppliers
vendors
business
partners
financial
condition
one
well
employees
global
economy
whole
material
effect
foregoing
could
also
adversely
impact
us
situation
changing
rapidly
additional
impacts
may
arise
currently
aware
may
exacerbate
previously
identified
risks
risks
uncertainties
also
include
uncertainties
discussed
identified
public
filings
sec
amf
made
sanofi
including
listed
risk
factors
cautionary
statement
regarding
statements
sanofi
annual
report
form
year
ended
december
required
applicable
law
sanofi
undertake
obligation
update
revise
information
statements
translate
bio
cautionary
note
regarding
statements
press
release
contains
statements
within
meaning
private
securities
litigation
reform
act
statements
include
limited
regarding
goal
initiate
phase
clinical
trial
fourth
quarter
potential
promising
candidate
clinical
development
development
mrna
vaccine
candidate
potential
elicit
robust
immune
response
translate
bio
beliefs
regarding
broad
applicability
mrt
platform
translate
bio
plans
strategies
prospects
business
including
lead
development
programs
continued
development
mrna
vaccines
treatment
infectious
diseases
words
anticipate
believe
continue
could
estimate
expect
forward
intend
may
plan
potential
predict
project
target
would
similar
expressions
intended
identify
statements
although
statements
contain
identifying
words
statements
subject
numerous
important
factors
risks
uncertainties
may
cause
actual
events
results
differ
materially
current
expectations
beliefs
including
limited
current
potential
future
impacts
pandemic
translate
bio
business
financial
condition
operations
liquidity
translate
bio
ability
advance
development
platform
programs
including
without
limitation
vaccine
development
program
generally
specifically
timelines
projects
demonstrate
requisite
safety
efficacy
product
candidates
replicate
clinical
trials
positive
findings
preclinical
studies
successful
advancement
collaboration
agreement
translate
bio
sanofi
uncertainties
relating
discovery
development
vaccine
candidates
based
mrna
specifically
relates
novel
coronavirus
content
timing
decisions
made
food
drug
administration
regulatory
authorities
investigational
review
boards
clinical
trial
sites
including
decisions
relates
ongoing
planned
clinical
trials
translate
bio
ability
obtain
maintain
enforce
necessary
patent
intellectual
property
protection
availability
significant
cash
required
fund
operations
competitive
factors
general
economic
market
conditions
important
risk
factors
set
forth
caption
risk
factors
translate
bio
quarterly
report
form
fiscal
quarter
ended
june
filed
securities
exchange
commission
august
subsequent
filings
made
translate
bio
statements
contained
press
release
speak
date
hereof
translate
bio
specifically
disclaims
obligation
update
statement
whether
result
new
information
future
events
otherwise
attachment
